Aripiprazole
Product Images NDC 70934-662

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 70934-662). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Denton Pharma, Inc. Dba Northwind Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (70934 662 30 Master Bottle Label Approval Rev A 04 20)

Aripiprazole Tablets USP 5 mg label displaying the product name, strength, dosage form, and quantity of 30 tablets. Label includes Rx only status, storage instructions to store at 20° to 25°C, and cautions such as keeping out of reach of children. Manufacturer is Denton Pharma, Inc. dba Northwind Pharmaceuticals. The label also features multiple NDC numbers and placeholders for lot number and expiration date.*

FDA Label Image

Figure 1 (Aripiprazole Figure 1)

A chart titled 'Effect of Other Drugs on Aripiprazole' showing fold change and 90% confidence intervals of Aripiprazole pharmacokinetics (AUC and Cmax) when coadministered with various drugs, including CYP3A4 inhibitors and inducers, CYP2D6 inhibitor, gastric acid blockers, and others like valproate, lithium, and lorazepam. The x-axis represents change relative to reference (without interacting drug).*

FDA Label Image

Figure 2 (Aripiprazole Figure 2)

A chart showing the effect of various drugs on the pharmacokinetics of aripiprazole, specifically the fold change in Dehydro-Aripiprazole with 90% confidence intervals. The x-axis represents change relative to reference without interacting drug, ranging from 0.5 to 3.0. Drugs listed on the y-axis include CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitor (quinidine), CYP3A4 inducer (carbamazepine), gastric acid blockers (famotidine), and others (valproate, lithium, lorazepam), with their impact on AUC and Cmax indicated.*

FDA Label Image

Figure 3 (Aripiprazole Figure 3)

A forest plot illustrating the effect of aripiprazole on the pharmacokinetics of various drugs. The x-axis indicates the change relative to reference (without interacting drug), ranging from 0.5 to 3.0. Various drugs metabolized by different enzymes like CYP2D6, CYP2C9, and UGT1A4 are listed on the y-axis with fold change and 90% confidence intervals shown as horizontal lines and squares indicating the effect size.*

FDA Label Image

Figure 4 (Aripiprazole Figure 4)

A pharmacokinetic graph titled 'Aripiprazole Fold Change and 90% CI,' showing fold changes in AUC and Cmax relative to reference across special populations, including CYP2D6 metabolizer status, gender, age, hepatic and renal impairment. The horizontal axis depicts change relative to reference, and data points include confidence intervals.*

FDA Label Image

Figure 5 (Aripiprazole Figure 5)

A pharmacokinetic chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing changes relative to reference for AUC and Cmax parameters across different factors including CYP2D6 metabolizer status, gender, age, hepatic impairment (mild, moderate, severe), and severe renal impairment. Data points with confidence intervals are plotted along a horizontal axis representing fold change values.*

FDA Label Image

Figure-6 (Aripiprazole Figure 6)

A Kaplan-Meier curve showing the proportion of subjects with relapse over days from randomization, comparing Aripiprazole (blue solid line) and placebo (red dashed line). Below the x-axis, the number of subjects at risk is listed for both groups at multiple time points up to 182 days.*

FDA Label Image

Figure-7 (Aripiprazole Figure 7)

A Kaplan-Meier curve showing the proportion of subjects with relapse over days from randomization in a clinical trial comparing ARIPIPRAZOLE with placebo. The graph includes a legend identifying ARIPIPRAZOLE (solid blue line) and placebo (dashed red line). Below the x-axis, the number of subjects at risk for each group is displayed at multiple time points up to 182 days.*

FDA Label Image

Figure-8 (Aripiprazole Figure 8)

A Kaplan-Meier curve comparing the proportion of relapse over time in days from randomization between two groups: ARIPIPRAZOLE and placebo. The graph shows the proportion with relapse on the y-axis and days on the x-axis, with ARIPIPRAZOLE represented by a solid blue line and placebo by a dashed red line. Numbers of subjects at risk for each group are displayed below the x-axis at various time points.*

FDA Label Image

Aripiprazole Chemical Structure (Aripiprazole Structure)

Chemical structure of aripiprazole, showing its complex arrangement of chlorinated phenyl, piperazine, and quinolinone components, consistent with the active ingredient aripiprazole.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.